Sunday 18 October 2026
Export IBO’s income statement to Excel — free account
Impact Biomedical Inc.
Impact Biomedical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32,000.00, down 36.0% from fiscal 2022. In the quarter to June 2026, revenue fell 57.1%, EPS grew 99.5% and free cash flow grew 167.7%, each against the same quarter a year earlier.
2.68
0.48
−15.19%
Follow IBO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.52 |
P/S ratio |
0.00 | 194.72 | 1,661.37 | 1,419.98 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(13.26) | 161.29 | (139.64) | 105.74 | |
P/B ratio |
0.00 | 1.03 | 4.40 | 3.55 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.00 | 291.89 | 1,865.24 | 1,647.44 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.41) | (12.66) | (43.51) | (113.50) | |
EV/FCF |
(5.37) | (12.54) | (43.04) | (109.62) | |
Quick Ratio |
0.00 | 0.01 | 0.01 | 0.00 | |
Current Ratio |
0.04 | 0.35 | 0.22 | 0.16 | |
Net Debt/EBITDA |
0.02 | 0.00 | 0.01 | 0.02 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.42 | 0.02 | 0.20 | (0.67) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(3.62) | — | — | — | |
Research and Development Expense of Revenue |
288.89% | 1,571.43% | 657.14% | 2,533.33% | |
Selling, General and Administrative Expense of Revenue |
1,461.11% | 1,714.29% | 23,157.14% | 5,566.67% | |
Intangible Assets out of Total Assets |
0.95 | 0.98 | 0.98 | 0.98 | |
Share Based Compensation of Revenue |
(1,050.00%) | 114.29% | 20,571.43% | 0.00% | |
Graham Net Nets |
(3.22) | (0.09) | (0.03) | (0.05) | |
Graham Number |
101.67 | 0.00 | 0.00 | 20.28 | |
Earnings Yield |
(590.83%) | (75.36%) | (48.47%) | 191.37% | |
Free Cash Flow Yield |
(36.83%) | (11.95%) | (2.61%) | (1.06%) | |
Revenue per Share |
0.02 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.64) | 0.04 | (0.05) | 0.06 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.64) | 0.04 | (0.05) | 0.06 | |
Cash per Share |
0.01 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
(9.17) | 6.23 | 1.72 | 1.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(9.17) | 6.23 | 1.72 | 1.64 | |
Free Cash Flow |
(0.61) | 0.10 | (0.46) | 0.47 | |
Working Capital |
(22.88) | (0.75) | (1.31) | (1.72) | |
Net Current Asset Value |
(26.14) | (1.44) | (2.00) | (2.41) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.07 | 0.07 | — | — | |
Average Payables |
0.79 | 0.33 | 0.49 | 0.51 | |
Average Inventory |
— | — | 0.28 | 0.27 | |
Average Assets |
32.45 | 18.85 | 18.57 | 17.90 | |
Average Common Equity |
12.69 | 11.37 | 10.73 | 3.29 |
Columns are period end dates · fundamentals updated 2 Oct 2026